New drug price re-evaluation system will affect sales of domestic pharmaceutical industry

Published: 2002-11-26 07:00:00

Updated: 2002-11-26 07:00:00

The envisaged drug price re-evaluation system seems likely to significantly affect large-sized and foreign-invested pharmaceutical firms rather than medium- and small-sized firms, according to Hanyang Securities.

Hanyang Securities said that under the new system, 31 foreign-invested firms wil...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK